TTY Biopharm Co

TTY Biopharm Co EBIT

The EBIT of TTY Biopharm Co (4105.TWO) as of Nov 3, 2026 is 1.70 B TWD. In the previous year, EBIT was 1.39 B TWD — a change of 22.32% (higher).

EBIT

1.70 BTWD

YoY

22.32%

Last updated:

In 2025, TTY Biopharm Co's EBIT was 1.70 B TWD, a 22.32% increase from the 1.39 B TWD EBIT recorded in the previous year.

The TTY Biopharm Co EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2020
1.21 B TWD
Jan 1, 2021
1.11 B TWD
Jan 1, 2022
1.43 B TWD
Jan 1, 2023
1.44 B TWD
Jan 1, 2024
1.39 B TWD
Jan 1, 2025
1.70 B TWD
Jan 1, 2026 (e)
2.49 B TWD
Jan 1, 2027 (e)
2.53 B TWD
The TTY Biopharm Co EBIT history
YEAREBITYoY
est2.53 BTWD+1.63%
est2.49 BTWD+46.13%
1.70 BTWD+22.32%
1.39 BTWD-3.50%
1.44 BTWD+1.22%
1.43 BTWD+28.18%
1.11 BTWD-8.14%
1.21 BTWD-0.92%
1.22 BTWD+15.42%
1.06 BTWD-15.70%
1.26 BTWD+6.55%
1.18 BTWD+49.37%
789.79 MTWD+133.60%
338.10 MTWD-0.52%
339.86 MTWD-47.96%
653.14 MTWD+19.35%
547.23 MTWD+0.73%
543.24 MTWD+23.40%
440.23 MTWD-3.32%
455.35 MTWD+23.56%
368.51 MTWD+35.54%
271.88 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TTY Biopharm Co Revenue

TTY Biopharm Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
4.22 B TWD
1.21 B TWD
924.18 M TWD
Jan 1, 2021
4.54 B TWD
1.11 B TWD
831.89 M TWD
Jan 1, 2022
5.06 B TWD
1.43 B TWD
1.09 B TWD
Jan 1, 2023
5.51 B TWD
1.44 B TWD
1.13 B TWD
Jan 1, 2024
5.89 B TWD
1.39 B TWD
1.45 B TWD
Jan 1, 2025
6.45 B TWD
1.70 B TWD
1.56 B TWD
Jan 1, 2026 (e)
7.03 B TWD
2.49 B TWD
1.81 B TWD
Jan 1, 2027 (e)
7.29 B TWD
2.53 B TWD
1.84 B TWD

TTY Biopharm Co Margins

TTY Biopharm Co stock margins

The TTY Biopharm Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of TTY Biopharm Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for TTY Biopharm Co.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
61.70 %
28.70 %
21.89 %
Jan 1, 2021
61.03 %
24.54 %
18.34 %
Jan 1, 2022
59.69 %
28.19 %
21.62 %
Jan 1, 2023
59.70 %
26.23 %
20.50 %
Jan 1, 2024
57.94 %
23.65 %
24.60 %
Jan 1, 2025
57.66 %
26.42 %
24.16 %
Jan 1, 2026 (e)
57.66 %
35.42 %
25.70 %
Jan 1, 2027 (e)
57.66 %
34.73 %
25.20 %

TTY Biopharm Co Stock analysis

What does TTY Biopharm Co do? TTY Biopharm Co Ltd generates revenue through pharmaceutical and chemical drug production, primarily targeting domestic and overseas markets. The company's six business segments include Cancer Drug, Healthcare, Anti-Infective Drug, Domestic Cardiovascular and Gastrointestinal Drug, Mainland Medical Drug, and Other segments. Key products are oncology medicines such as anti-cancer and auxiliary drugs, anti-infective medicines like back-line antimicrobial agents and influenza vaccines, and healthcare medicines covering gastrointestinal, bone, metabolic health care, and infection treatment. Domestic and overseas customers purchase these products through the company's distribution channels. The Cancer Drug segment focuses on oncology medicines, including anti-cancer and auxiliary drugs, while the Anti-Infective Drug segment offers back-line antimicrobial agents and influenza vaccines. Healthcare segment products target gastrointestinal, bone, and metabolic health care, alongside infection treatment drugs. Mainland Medical Drug segment serves the mainland market with medical drugs, and Other segment handles additional product lines. All products are distributed domestically and internationally. Domestic and overseas markets drive sales of TTY Biopharm's pharmaceutical portfolio. Customers include healthcare providers and distributors purchasing oncology, anti-infective, and healthcare medicines. The Mainland Medical Drug segment specifically caters to the mainland market, while other segments serve broader regional demands. Product distribution spans both local and global channels. TTY Biopharm Co is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing TTY Biopharm Co's EBIT

TTY Biopharm Co's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of TTY Biopharm Co's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

TTY Biopharm Co's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in TTY Biopharm Co’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about TTY Biopharm Co stock

EBIT of TTY Biopharm Co is 1.70 B TWD in 2025.

EBIT of TTY Biopharm Co changed from 1.39 B TWD to 1.70 B TWD, representing a 22.32% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT TTY Biopharm Co since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's TTY Biopharm Co historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — TTY Biopharm Co

All Key Metrics — TTY Biopharm Co